Acute myeloid leukemia affects about 22,720 people in the U.S. each year, with roughly 11,500 deaths annually, making new treatments essential. Menin inhibitors represent a major advance, targeting a molecular driver in up to 40% of AML cases.
These drugs block the interaction between the MEN1 protein and the KMT2A gene, which drives abnormal cell growth in tumors with NPM1 mutations or KMT2A-rearranged AML.
Two FDA-approved options now exist
Revumenib (Revuforj) and ziftomenib (Komzifti) are now FDA approved. In November 2025, ziftomenib gained approval for adults with relapsed or refractory NPM1-mutated AML who lack other options. The KO-MEN-001 trial showed a similar remission rate, with responses lasting a median of 5 months. Transfusion independence was reached by 21.2% of previously dependent patients.
Related: Choosing the Best Custom Stencils From Stencil Giant
Monitoring for serious side effects is critical
Differentiation syndrome is the most severe risk, requiring early recognition and immediate steroid treatment.
Hospitals should have a protocol in place before starting therapy, including temporary drug discontinuation in severe cases. QTc prolongation is another concern, though ziftomenib appears to avoid this issue, making it a potential option for patients with existing cardiac risks or those on other QT-prolonging drugs. Regular ECG monitoring remains standard for the class.
Drug interactions, especially with azole antifungals, demand close attention. These are commonly used in AML patients, so dose adjustments may be necessary.
Related: Growing (and Keeping) Your Beard: What Happens After You Stop Using Minoxidil?
Future use may expand beyond relapsed cases
Current approvals cover only relapsed or refractory AML, but trials are testing menin inhibitors as first-line treatments, post-transplant maintenance, and for molecular relapse. Early studies combining these drugs with azacitidine, venetoclax, or chemotherapy have shown promising response rates in newly diagnosed patients.
The MEN1 protein normally acts as a tumor suppressor, but in certain AML subtypes, it becomes oncogenic. This dual role explains why targeting it works for a subset of patients while leaving others unaffected.
Oncology pharmacists are most likely to encounter menin inhibitors in the relapsed setting. As research progresses, their role could grow across multiple stages of AML treatment.